MegaSporeBiotic™
SPORE-BASED PROBIOTIC | ANTIOXIDANT
MegaSporeBiotic™ is the first 100% spore-based, broad-spectrum probiotic clinically shown to improve leaky gut by 60% in just 30 days. This unique all-spore formula effectively RECONDITIONS the gut by increasing microbial diversity and encouraging the growth of key health-promoting, commensal gut bacteria. MegaSporeBiotic™ boasts a 5-year shelf-life, does not require refrigeration, and maintains efficacy during antibiotic therapy.
How to buy
Practitioner
PATIENT
A valid Practitioner account is required for direct purchases from our website. Let’s get you registered!
Subscribe & Save
I had been on Digestive Advantage for 5 years and saw little improvement. Within 3 days of being on MegaSpore I could not believe how much better I felt and still continue to feel since switching. The Best Probiotic out there!!!!
Angie BornoskiJUNE 19, 2018 AT 5:56 PM 
Our office LOVES this product. We can’t keep it on the shelve. We use the product ourselves and our patients are excited to try it. It has GREAT science behind it. We are always learning something new when we listen to Kiran talk about the products. We look forward to helping our patients with some of their chronic issues as well as continuing to help ourselves.
Robert E. TaylorAPRIL 27, 2018 AT 11:27 AM
When my son was 2.5 months old he was having some colicky symptoms. Crying during nursing and a hard belly. As soon as I started taking Mega sporebiotics the symptoms disappeared! I have continued taking it and recommend it to patients with a variety of symptoms.
Erica DiCosmoDECEMBER 8, 2017 AT 2:14 PM
Still using with different conditions with patients…the most exciting was an elderly patient with C-diff that no one could clear up, including Hospitalization…is doing much better! Thank you God and Microbiome Labs!
David PhilipsonNOVEMBER 20, 2017 AT 4:57 PM
1
MegaSporeBiotic™
Recondition
2
MegaPreBiotic™
Reinforce
3
MegaMucosa™
Rebuild
At a Glance
The 1st probiotic to PROTECT its human host
Among non-communicable diseases, intestinal permeability (metabolic endotoxemia) is the #1 cause of morbidity and mortality worldwide. Metabolic endotoxemia is a condition that stems from dysbiosis and a breakdown of intestinal barrier function. Intestinal permeability is present in most chronic diseases and is believed to be a major driver of many conditions. MegaSporeBiotic is clinically shown to reduce intestinal permeability by 60%, when compared to the placebo control group, in just 30 days without any additional interventions.
Conditions associated with Metabolic Endotoxemia/Intestinal Permeability:
- Depression
- Autoimmunity
- Anxiety
- Alzheimer’s
- Memory Loss
- Anorexia
- Parkinson’s
- Hypogonadism
- Leptin Resistance
- Chronic Pain
Reduce LPS Translocation
Reduce Systemic Inflammation
Repair Leaky Gut
Ingredients
Dosing Instructions
Start with 1/2 capsule or 1 full capsule with food and slowly increase to 2 capsules per day using the following protocol.
If 1 capsule every other day is too strong, try starting with 1/2 capsules or even 1/4 capsule in some cases. Possible symptoms may include abdominal cramping, loose stools, and changes in bowel movements. Though these symptoms may be uncomfortable, they are a sign that the product is working! Symptoms should resolve within 2-3 days.
Week 1
1 capsule every other day
Week 2
1 capsule daily
Week 3+
2 capsules daily
Research
McFarlin BK, Henning AL, Carbajal KM.
Oral spore-based probiotic supplementation was associated with reduced incidence of post-prandial dietary endotoxin, triglycerides, and disease risk biomarkers. World J Gastrointest Pathophysiol. 2017 Aug 15; 8(3): 117–126.
Rhee KJ, Sethupathi P, Driks A, et al.
Role of commensal bacteria in development of gut-associated lymphoid tissue and preimmune antibody repertoire. J Immunol. 2004;172(2):1118-24.
De Punder K, Pruimboom L.
Stress induces endotoxemia and low-grade inflammation by increasing barrier permeability. Front Immunol. 2015;15(6):223.
Gong Y, Li H, Li Y.
Effects of Bacillus subtilis on epithelial tight junctions of mice with inflammatory bowel disease. J Interferon Cytokine Res. 2016;36(2).
Samanya M, Yamauchi K.
Histological alterations of intestinal villi in chickens fed dried Bacillus subtilis var. natto. Comp Biochem Physiol A Mol Integr Physiol. 2002;133(1):95-104.
Tam NKM, Uyen NQ, Hong HA, et al.
The Intestinal Life Cycle of Bacillus subtilis and Close Relatives. Journal of Bacteriology. 2006;188(7):2692-2700.
“Survival of Probiotics in Simulated Gastric Fluid.”
Food Science Center Report. Silliker Labs. RPN 16663. August 24, 2013.
Gibson GR, Rouzaud G, Brostoff J, et al.
An evaluation of probiotic effects in the human gut: microbial aspects. Final Technical report. FSA project ref G01022.
Lefevre M, Racedo SM, Ripert G, et al.
Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study. Immun Aging. 2015;12:24.
Serra CR, Earl AM, Barbosa TM, et al.
Sporulation during Growth in a Gut Isolate of Bacillus subtilis. J Bacteriol. 2014;196(23):4184-4196.
Hong HA, Khaneja R, Tam NMK, et al.
Bacillus subtilis isolated from the human gastrointestinal tract. Res Microbiol. 2009;160(2):134-143.
Mandel DR, Eichas K, Holmes J.
Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern Med. 2010;10:1.
Marseglia GL, Tosca M, Cirillo I, et al.
Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study. Ther Clin Risk Manag. 2007;3(1):13-7.
Urdaci MC, Bressollier P, Pinchuk I, et al.
Bacillus clausii probiotic strains: antimicrobial and immunomodulatory activities. J Clin Gastroenterol. 2004;38(6 Suppl):S86-90.
Nista EC, Candelli M, Cremonini F, et al.
Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther. 2004 Nov;20(10):1181-8.
Gabrielli M, Lauritano EC, Scarpellini E, et al.
Bacillus clausii as a Treatment of Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2009;104(5):1327-8.
Di Caro S, Tao H, Grillo A, et al.
Bacillus clausii effect on gene expression pattern in small bowel mucosa using DNA microarray analysis. Eur J Gastroenterol Hepatol. 2005;17(9):951-60.
Ciprandi G, Tosca MA, Milanese M, et al.
Cytokines evaluation in nasal lavage of allergic children after Bacillus clausii administration: A pilot study. Pediatr Allergy Immunol. 2004;15(2):148-51.
Casula G, Cutting SM.
Bacillus Probiotics: Spore Germination in the Gastrointestinal Tract. App Environ Microb. 2002;68(5):2344-2352.